Research
Hormonal
The number of incident GLP-1 RA users in France increased from 5117 in January 2017 to 15,193 in June 2023.
Healthcare providers should be aware of the significant increase in GLP-1 RA prescriptions.
StrongSupportsmedium confidence
As incident GLP-1 RA users increased (5117 in January 2017 to 15 193 in June 2023).
Why this rating
Based on the analysis of a national health database.
Source
Use and Potential Misuse of Glucagon-Like Peptide-1 Receptor Agonists in France: A Nationwide Cohort Study
Nathan du Soulier et al. · Value in Health · 2025
DOI 10.1016/j.jval.2025.06.001
cohort · n=15193Cited 6×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →